The mixed model developed by us could be particularly useful for exploring such targeted interventions, providing a unique opportunity to understand how modifying one pathway (such as APC signaling) might mitigate the clinical manifestations of both hemophilia and SPCD. The gene discussed is APC; the disease is systemic primary carnitine deficiency disease.